RiverPark Advisors’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-308
Closed -$20.6K 133
2024
Q3
$20.6K Sell
308
-89
-22% -$7.31K 0.02% 129
2024
Q2
$45K Hold
397
0.04% 117
2024
Q1
$55.1K Buy
+397
New +$49.9K 0.05% 111
2022
Q1
Sell
-95,884
Closed -$12.9M 200
2021
Q4
$12.9M Sell
95,884
-20,768
-18% -$2.98M 1.55% 24
2021
Q3
$15.9M Sell
116,652
-34,840
-23% -$4.39M 1.95% 18
2021
Q2
$16.2M Hold
151,492
2.06% 16
2021
Q1
$13.6M Hold
151,492
2.24% 18
2020
Q4
$14M Buy
151,492
+55,344
+58% +$4.94M 2.46% 15
2020
Q3
$9.91M Buy
96,148
+26,124
+37% +$2.73M 2.23% 18
2020
Q2
$7.1M Buy
70,024
+1,672
+2% +$150K 2.21% 19
2020
Q1
$4.6M Buy
+68,352
New +$4.25M 2.64% 11

Other funds holding DXCM

RiverPark Advisors's DXCM Position: Q4 2024 in Review

RiverPark Advisors sold out of DexCom (DXCM) in Q4 2024, closing a stake of 308 shares — an estimated $20.6K sold.

RiverPark Advisors first reported a position in DXCM in Q1 2020 and held it in 11 quarters. The position peaked at $16.2M in Q2 2021. 950 funds tracked by Wall St. Rank hold DXCM as of Q4 2024.

  • RiverPark Advisors reported no remaining DexCom position as of Q4 2024 after selling out during the quarter.
  • RiverPark Advisors sold 308 DexCom shares in Q4 2024, an estimated $20.6K.
  • RiverPark Advisors first reported a position in DexCom in Q1 2020 and held it in 11 quarters.
  • RiverPark Advisors's DexCom position peaked at $16.2M in Q2 2021.
  • 950 funds tracked by Wall St. Rank held DexCom as of Q4 2024.

Based on RiverPark Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.